AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18090460 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (500 to 3000 mg/d)
Number of subjects: 15
Study 18090460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14985605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (lay delivered intervention by promotoras)
Number of subjects: 143
Study 14985605 — intervention group
Group type: COMPARATOR
Intervention: Control group (measurement only)
Number of subjects: 143
Study 12608504 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace metal supplementation
Number of subjects: 0
Study 12608504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Reference Intakes for older adults
Number of subjects: 0
Study 9807979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg three times daily
Number of subjects: 19
Study 9807979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7695971 — intervention group
Group type: EXPERIMENTAL
Intervention: OND 8 mg tablet
Number of subjects: 259
Study 7695971 — intervention group
Group type: COMPARATOR
Intervention: ALI 150 mg i.v. injection followed by ALI 50 mg tablet
Number of subjects: 259
Study 2623077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) 3 IDU/kg bodyweight
Number of subjects: 13
Study 2623077 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (CT) 0.1 IU/kg bodyweight
Number of subjects: 13
Study 2623077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 340182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal, 375 mg twice daily
Number of subjects: 40
Study 340182 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone, 200 mg twice daily
Number of subjects: 40
Study 31550617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) with the anode over the left posterior parietal cortex after reactivation
Number of subjects: 27
Study 31550617 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) with the anode over the left posterior parietal cortex without reactivation
Number of subjects: 27
Study 31550617 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) with the anode over a control site (primary visual cortex) after reactivation
Number of subjects: 27
Study 27836220 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (KT) applied to ankles
Number of subjects: 20
Study 26163096 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month trastuzumab arm
Number of subjects: 3380
Study 26163096 — intervention group
Group type: COMPARATOR
Intervention: 6-month trastuzumab arm
Number of subjects: 3380
Study 26163096 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 3380
Study 24127622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56
Study 24127622 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 56
Study 20370794 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 134
Study 20370794 — intervention group
Group type: COMPARATOR
Intervention: fluvastatin 80 mg XL
Number of subjects: 134
Study 19690081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg NBI-6024
Number of subjects: 188
Study 19690081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg NBI-6024
Number of subjects: 188
Study 19690081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg NBI-6024
Number of subjects: 188
Study 19690081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 19690081 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.1 mg, 0.5 mg, 1.0 mg NBI-6024, and placebo)
Number of subjects: 188
Study 17259154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 5000 U/kg
Number of subjects: 40
Study 17259154 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 40
Study 15526248 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 149
Study 15526248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 11474540 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal neurostimulation (VNS)
Number of subjects: 48
Study 11474540 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated CAD patients)
Number of subjects: 48
Study 9506192 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (including long-acting dihydropyridines and nondihydropyridine agents)
Number of subjects: 0
Study 9506192 — intervention group
Group type: COMPARATOR
Intervention: Short-acting agents (e.g., nifedipine)
Number of subjects: 0
Study 8036828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms yeast‐derived HBsAg
Number of subjects: 112
Study 8036828 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms yeast‐derived HBsAg
Number of subjects: 112
Study 8036828 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication at the time of vaccination
Number of subjects: 112
Study 8036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of medication at the time of vaccination
Number of subjects: 112
Study 3053313 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (BAY g 5421)
Number of subjects: 12
Study 3053313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29501740 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles intervention
Number of subjects: 553
Study 29501740 — intervention group
Group type: COMPARATOR
Intervention: Healthy Finances (attention control)
Number of subjects: 553
Study 27259675 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected intercourse
Number of subjects: 33
Study 27259675 — intervention group
Group type: COMPARATOR
Intervention: Vaginal inoculation with male partner's semen
Number of subjects: 33
Study 27259675 — intervention group
Group type: COMPARATOR
Intervention: Sampling frequency and home versus clinic sampling
Number of subjects: 33
Study 25714127 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL) intervention
Number of subjects: 267
Study 25714127 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 267
Study 23445320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg·kg(‐1))
Number of subjects: 50
Study 23445320 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (2 mg·kg(‐1))
Number of subjects: 50
Study 20130841 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (15-30 mg/day)
Number of subjects: 55
Study 20130841 — intervention group
Group type: COMPARATOR
Intervention: metformin (500-750 mg/day)
Number of subjects: 55
Study 18070142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine infusion
Number of subjects: 32
Study 18070142 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nifedipine
Number of subjects: 32
Study 18070142 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Nitroglycerine and Nifedipine)
Number of subjects: 32
Study 15995024 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg IVIG over 2 days
Number of subjects: 95
Study 15995024 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g/kg IVIG over 5 days
Number of subjects: 95
Study 15995024 — intervention group
Group type: COMPARATOR
Intervention: 2 g/kg IVIG administered over 2 days
Number of subjects: 95
Study 15995024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days treatment
Number of subjects: 95
Study 15995024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day regimen
Number of subjects: 95
Study 12850889 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drink with antioxidants (450 ml/day for 4 weeks)
Number of subjects: 98
Study 12850889 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (450 ml/day for 4 weeks)
Number of subjects: 98
Study 10566127 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue B-glucose
Number of subjects: 46
Study 10566127 — intervention group
Group type: COMPARATOR
Intervention: Glucometer IV (Bayer), Glucotrend (Roche Diagnostics), One touch (Life Scan, Johnson & Johnson)
Number of subjects: 46
Study 10566127 — intervention group
Group type: COMPARATOR
Intervention: Different glucose meters
Number of subjects: 46
Study 10566127 — intervention group
Group type: COMPARATOR
Intervention: Glucose meters in clinical departments
Number of subjects: 46
Study 9235072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise intervention (12 weekly group sessions, 1 individual counseling session, 6 biweekly follow-up sessions)
Number of subjects: 64
Study 9235072 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise intervention
Number of subjects: 64
Study 9235072 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 class on metabolic control and 2 mailings of nutrition information)
Number of subjects: 64
Study 1662884 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg b.i.d. for 28 days
Number of subjects: 112
Study 7068294 — intervention group
Group type: EXPERIMENTAL
Intervention: Static strength training program with 90% of the maximal static strength, 9 weeks, three times a week
Number of subjects: 29
Study 7068294 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 31358540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 0.1 to 20 mg/kg or ≥10 mg/kg every 3 weeks
Number of subjects: 45
Study 30238189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 100
Study 30238189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA)
Number of subjects: 100
Study 30238189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR)
Number of subjects: 100
Study 30238189 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (IVTA, IVR, IVA)
Number of subjects: 100
Study 26842262 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinkers
Number of subjects: 42
Study 26842262 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 42
Study 26842262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 26842262 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 42
Study 24532394 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 112
Study 24532394 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 112
Study 23351178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compressions with the LUCAS™ device
Number of subjects: 2500
Study 23351178 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual cardiopulmonary resuscitation (CPR)
Number of subjects: 2500
Study 23351178 — intervention group
Group type: EXPERIMENTAL
Intervention: Post mortem examinations in 300 patients
Number of subjects: 2500
Study 20800887 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular muscle exercises
Number of subjects: 731
Study 20800887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 731
Study 17392697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat (15% fat), high‐fiber (18 g/1000 kcal) diet supplemented with 40 g soy protein isolate (n=26)
Number of subjects: 40
Study 17392697 — intervention group
Group type: COMPARATOR
Intervention: USDA recommended diet (n=14)
Number of subjects: 40
Study 16908468 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive coping strategies
Number of subjects: 85
Study 16908468 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological quality of life (QOL)
Number of subjects: 85
Study 12651636 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) combined with artificial blood substitutes (ABS)
Number of subjects: 204
Study 12651636 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic replacement of blood loss with colloid
Number of subjects: 204
Study 10804328 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid (60 ml/h) and heparin (900 U/h) for 5.5 h
Number of subjects: 9
Study 10804328 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 9
Study 8778696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoue balloon catheter
Number of subjects: 31
Study 8778696 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon catheter
Number of subjects: 31
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prealbumin in patients with acute viral hepatitis
Number of subjects: 78
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prealbumin in patients with chronic active hepatitis
Number of subjects: 78
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prealbumin in patients with cirrhosis
Number of subjects: 78
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prealbumin in patients with hepatoma
Number of subjects: 78
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin in patients with acute viral hepatitis
Number of subjects: 78
Study 8065177 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin in patients with chronic liver diseases
Number of subjects: 78
Study 8065177 — intervention group
Group type: COMPARATOR
Intervention: Serum prealbumin in normal subjects
Number of subjects: 78
Study 3716785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Extraction (VE)
Number of subjects: 47
Study 3716785 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 47
Study 3716785 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous delivery)
Number of subjects: 47
Study 28631989 — intervention group
Group type: EXPERIMENTAL
Intervention: High rapport condition
Number of subjects: 98
Study 28631989 — intervention group
Group type: COMPARATOR
Intervention: Low rapport condition
Number of subjects: 98
Study 28068165 — intervention group
Group type: COMPARATOR
Intervention: Head Cooling (HC)
Number of subjects: 27
Study 28068165 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm Cooling (FC)
Number of subjects: 27
Study 28068165 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 24243632 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise (MIE)
Number of subjects: 18
Study 24243632 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise (HIE)
Number of subjects: 18
Study 24243632 — intervention group
Group type: COMPARATOR
Intervention: Control (1 hour of seated rest)
Number of subjects: 18
Study 24243632 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between MIE and HIE
Number of subjects: 18
Study 25534331 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (Group 1, n=20)
Number of subjects: 40
Study 25534331 — intervention group
Group type: COMPARATOR
Intervention: No TAP block (Group 2, n=20)
Number of subjects: 40
Study 22925365 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar vessel sealing
Number of subjects: 100
Study 22925365 — intervention group
Group type: COMPARATOR
Intervention: Conventional clamping and suturing
Number of subjects: 100
Study 20655660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese acupuncture (verum)
Number of subjects: 424
Study 20655660 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (sham)
Number of subjects: 424
Study 20655660 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative orthopaedic treatment (COT)
Number of subjects: 424
Study 17717682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol in juice (1.4 g/l)
Number of subjects: 19
Study 17717682 — intervention group
Group type: COMPARATOR
Intervention: Juice (placebo)
Number of subjects: 19
Study 15758565 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous dexamethasone suppression test
Number of subjects: 31
Study 12036821 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1450 mg/d) and vitamin D (10 microg (400 IU)/d)
Number of subjects: 99
Study 12036821 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, vitamin D, and other nutrients (multinutrient supplement)
Number of subjects: 99
Study 12036821 — intervention group
Group type: COMPARATOR
Intervention: Dietary instruction (dietary control group)
Number of subjects: 99
Study 12036821 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 99
Study 10208191 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 15 L/min
Number of subjects: 16
Study 10208191 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 30 L/min
Number of subjects: 16
Study 10208191 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 60 L/min
Number of subjects: 16
Study 10208191 — intervention group
Group type: COMPARATOR
Intervention: Albuterol via pMDI inhaled at 30 L/min
Number of subjects: 16
Study 10208191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8674265 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based exercise test analyzer
Number of subjects: 60
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics alone (23%)
Number of subjects: 714
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers alone (32%)
Number of subjects: 714
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic and beta blocker (38%)
Number of subjects: 714
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with vasodilators (9%)
Number of subjects: 714
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Other forms of therapy (5%)
Number of subjects: 714
Study 1844749 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 714
Study 6301804 — intervention group
Group type: EXPERIMENTAL
Intervention: Renitidin
Number of subjects: 100
Study 6301804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrozepin
Number of subjects: 100
Study 6301804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31428433 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (delivered over eight sessions as weekly one‐on‐one, face‐to‐face 40‐min consultations)
Number of subjects: 55
Study 31428433 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pharmacological treatment and similar educational programmes)
Number of subjects: 55
Study 29134635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study 29871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning (Barbecue reposition maneuver)
Number of subjects: 62
Study 29871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Reposition plus drug treatment (Barbecue reposition maneuver + Alprostadil, Cinepazide, Betahistine)
Number of subjects: 62
Study 29871085 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning
Number of subjects: 62
Study 29871085 — intervention group
Group type: COMPARATOR
Intervention: Reposition plus drug treatment
Number of subjects: 62
Study 29871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 25730940 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji IX GP
Number of subjects: 30
Study 25730940 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji IX GP EXTRA
Number of subjects: 30
Study 25730940 — intervention group
Group type: EXPERIMENTAL
Intervention: GC EQUIA
Number of subjects: 30
Study 25730940 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Coat - EQUIA (light curing varnish)
Number of subjects: 30
Study 22196577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 60
Study 22196577 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital protocol (Control)
Number of subjects: 60
Study 20854342 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (20 min daily for 5 days)
Number of subjects: 80
Study 20854342 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard prenatal care)
Number of subjects: 80
Study 17983871 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.5 mg once daily
Number of subjects: 0
Study 17983871 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 4 or 5 mg once daily
Number of subjects: 0
Study 16027500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-Acupuncture therapy for 20 minutes
Number of subjects: 40
Study 16027500 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting on the bed)
Number of subjects: 40
Study 12492272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle brace
Number of subjects: 14
Study 12492272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 14
Study 12492272 — intervention group
Group type: COMPARATOR
Intervention: No stabilizer (control)
Number of subjects: 14
Study 10681792 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial ischemic preconditioning (Group IP)
Number of subjects: 20
Study 10681792 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 20
Study 9183983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 13
Study 9183983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 13
Study 9183983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9183983 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 13
Study 1380411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta, 250 U/kg
Number of subjects: 87
Study 1380411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta, 500 U/kg
Number of subjects: 87
Study 1380411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta, 1000 U/kg
Number of subjects: 87
Study 1380411 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 87